{"id":"F2021L00390","name":"National Health (Listed Drugs on F1 or F2) Determination 2021","slug":"national-health-listed-drugs-on-f1-or-f2-determination-2021","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":101628,"registerId":"commonwealth-F2021L00390-current","compilationNumber":null,"startDate":"2026-04-03","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health (Listed Drugs on F1 or F2) Determination 2021","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\ntitle: National Health (Listed Drugs on F1 or F2) Determination 2021\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n![Commonwealth Coat of Arms of Australia](image.001.png)\n\nNational Health (Listed Drugs on F1 or F2) Determination 2021\n\nPB 33 of 2021\n\nmade under section 85AB of the\n\nNational Health Act 1953\n\nCompilation No. 53\n\nCompilation date: 1 March 2026\n\nIncludes amendments: F2026L00179\n\nAbout this compilation\n\nThis compilation\n\nThis is a compilation of the National Health (Listed Drugs on F1 or F2) Determination 2021 that shows the text of the law as amended and in force on 1 March 2026 (the compilation date).\n\nThe notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.\n\nUncommenced amendments\n\nThe effect of uncommenced amendments is not shown in the text of the compiled law. The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au).\n\nApplication, saving and transitional provisions\n\nIf the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.\n\nEditorial changes\n\nFor more information about any editorial changes made in this compilation, see the endnotes.\n\nPresentational changes\n\nThe Legislation Act 2003 provides for First Parliamentary Counsel to make presentational changes to a compilation. Presentational changes are applied to give a more consistent look and feel to legislation published on the Register, and enable the user to more easily navigate those documents.\n\nModifications\n\nIf the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. Any modifications affecting the law are accessible on the Register.\n\nSelf‑repealing provisions\n\nIf a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.\n\n \n\n \n\n \n\nContents\n\n1 Name\n\n3 Authority\n\n5 Definitions\n\n6 Drugs on F1\n\n7 Drugs on F2\n\nSchedule 1—Drugs on F1\n\nSchedule 2—Drugs on F2\n\nEndnotes\n\nEndnote 1—About the endnotes\n\nEndnote 2—Abbreviation key\n\nEndnote 3—Legislation history\n\nEndnote 4—Amendment history\n\n \n\n1  Name\n\n (1) This instrument is the National Health (Listed Drugs on F1 or F2) Determination 2021.\n\n (2) This instrument may also be cited as PB 33 of 2021.\n\n3  Authority\n\n  This instrument is made under section 85AB of the National Health Act 1953.\n\n5  Definitions\n\n  In this instrument:\n\nAct means the National Health Act 1953.\n\n6  Drugs on F1\n\n  For the purposes of subsection 85AB(1) of the Act, the drugs mentioned in Schedule 1 are on F1.\n\n7  Drugs on F2\n\n  For the purposes of subsection 85AB(1) of the Act, the drugs mentioned in Schedule 2 are on F2.\n\nSchedule 1—Drugs on F1\n\nNote: See section 6.\n\n \n\n| Abacavir |\n| --- |\n| Abemaciclib |\n| Acalabrutinib |\n| Acetazolamide |\n| Aclidinium |\n| Adapalene with benzoyl peroxide |\n| Afatinib |\n| Albendazole |\n| Alectinib |\n| Alemtuzumab |\n| Alogliptin |\n| Amifampridine |\n| Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids |\n| Amino acid formula with carbohydrate, vitamins, minerals and trace elements without phenylalanine |\n| Amino acid formula with carbohydrate without phenylalanine |\n| Amino acid formula with fat, carbohydrate, vitamins and minerals without phenylalanine |\n| Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine |\n| Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine |\n| Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides |\n| Amino acid formula with fat, carbohydrate without methionine |\n| Amino acid formula with fat, carbohydrate without phenylalanine |\n| Amino acid formula with fat, carbohydrate without phenylalanine and tyrosine |\n| Amino acid formula with fat, carbohydrate without valine, leucine and isoleucine |\n| Amino acid formula with vitamins and minerals without lysine and low in tryptophan |\n| Amino acid formula with vitamins and minerals without methionine |\n| Amino acid formula with vitamins and minerals without methionine and supplemented with arachidonic acid and docosahexaenoic acid |\n| Amino acid formula with vitamins and minerals without methionine, threonine and valine, and low in isoleucine |\n| Amino acid formula with vitamins and minerals without phenylalanine |\n| Amino acid formula with vitamins and minerals without phenylalanine and tyrosine |\n| Amino acid formula with vitamins and minerals without valine, leucine and isoleucine |\n| Amino acid formula with vitamins and minerals without valine, leucine, isoleucine and supplemented with arachidonic acid and docosahexaenoic acid |\n| Amino acid formula with vitamins and minerals, low phenylalanine and supplemented with docosahexaenoic acid and arachidonic acid |\n| Amino acid formula with vitamins and minerals, without phenylalanine, tyrosine and supplemented with arachidonic acid and docosahexaenoic acid |\n| Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine |\n| Amino acid formula without phenylalanine |\n| Amino acid formula without valine, leucine and isoleucine |\n| Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids |\n| Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides |\n| Amino acids—synthetic, formula |\n| Amivantamab |\n| Amphotericin B |\n| Amylopectin, modified long chain |\n| Anakinra |\n| Anifrolumab |\n| Apalutamide |\n| Apixaban |\n| Apremilast |\n| Arachidonic acid and docosahexaenoic acid with carbohydrate |\n| Arginine with carbohydrate |\n| Armodafinil |\n| Artemether with lumefantrine |\n| Asciminib |\n| Asenapine |\n| Atezolizumab |\n| Atropine |\n| Auranofin |\n| Avacopan |\n| Avatrombopag |\n| Avelumab |\n| Axitinib |\n| Balsalazide |\n| Baricitinib |\n| Beclometasone |\n| Belzutifan |\n| Benralizumab |\n| Benzathine benzylpenicillin |\n| Benzatropine |\n| Benzydamine |\n| Benzylpenicillin |\n| Betaine |\n| Bimekizumab |\n| Binimetinib |\n| Blinatumomab |\n| Botulinum toxin type A purified neurotoxin complex |\n| Brentuximab vedotin |\n| Brexpiprazole |\n| Brigatinib |\n| Brivaracetam |\n| Brolucizumab |\n| Budesonide |\n| Burosumab |\n| Busulfan |\n| Cabotegravir |\n| Cabozantinib |\n| Calcitonin salmon |\n| Calcium |\n| Cannabidiol |\n| Capivasertib |\n| Carbohydrate, fat, vitamins, minerals and trace elements |\n| Carbohydrate, fat, vitamins, minerals and trace elements and supplemented with arachidonic acid and docosahexaenoic acid |\n| Carfilzomib |\n| Cariprazine |\n| Carmellose |\n| Carmustine |\n| Cemiplimab |\n| Ceritinib |\n| Cetrorelix |\n| Cetuximab |\n| Chlorambucil |\n| Chloramphenicol |\n| Chlormethine |\n| Chlorpromazine |\n| Chlortalidone |\n| Choriogonadotropin alfa |\n| Ciclesonide |\n| Citrulline |\n| Citrulline with carbohydrate |\n| Clobetasol |\n| Clostridium Botulinum Type A Toxin‑haemagglutinin Complex |\n| Cobimetinib |\n| Codeine |\n| Colestyramine |\n| Corifollitropin alfa |\n| Cortisone |\n| Crizotinib |\n| Cytarabine |\n| Dabrafenib |\n| Dantrolene |\n| Dapagliflozin |\n| Daratumumab |\n| Darbepoetin alfa |\n| Darolutamide |\n| Decitabine with cedazuridine |\n| Deferiprone |\n| Degarelix |\n| Desmopressin |\n| Deucravacitinib |\n| Dexamfetamine |\n| Difelikefalin |\n| Diphtheria and tetanus vaccine, adsorbed, diluted for adult use |\n| Diroximel fumarate |\n| Disopyramide |\n| Dolutegravir |\n| Dornase alfa |\n| Dostarlimab |\n| Dulaglutide |\n| Dupilumab |\n| Durvalumab |\n| Eculizumab |\n| Edaravone |\n| Eflornithine |\n| Elafibranor |\n| Eletriptan |\n| Elotuzumab |\n| Eltrombopag |\n| Empagliflozin |\n| Emtricitabine with tenofovir alafenamide |\n| Encorafenib |\n| Enfortumab vedotin |\n| Entacapone |\n| Entrectinib |\n| Enzalutamide |\n| Epcoritamab |\n| Epoetin Alfa |\n| Epoetin Beta |\n| Epoetin Lambda |\n| Eptinezumab |\n| Esketamine |\n| Essential amino acids formula |\n| Essential amino acids formula with minerals and vitamin C |\n| Essential amino acids formula with vitamins and minerals |\n| Estriol |\n| Ethosuximide |\n| Etonogestrel |\n| Etrasimod |\n| Etravirine |\n| Evolocumab |\n| Faricimab |\n| Febuxostat |\n| Fenfluramine |\n| Ferric carboxymaltose |\n| Ferric derisomaltose |\n| Ferrous fumarate |\n| Ferrous Sulfate |\n| Finerenone |\n| Flupentixol decanoate |\n| Fluticasone furoate |\n| Folic acid |\n| Follitropin delta |\n| Fondaparinux |\n| Formoterol |\n| Foslevodopa with foscarbidopa |\n| Framycetin |\n| Fremanezumab |\n| Fusidic acid |\n| Galcanezumab |\n| Gemtuzumab ozogamicin |\n| Gilteritinib |\n| Glecaprevir with pibrentasvir |\n| Glofitamab |\n| Glucagon |\n| Glucose and ketone indicator urine |\n| Glycine with carbohydrate |\n| Glycomacropeptide and essential amino acid formula with vitamins, minerals, and low in tyrosine and phenylalanine |\n| Glycomacropeptide and essential amino acids with vitamins and minerals |\n| Glycomacropeptide formula with amino acids and low phenylalanine |\n| Glycomacropeptide formula with amino acids, vitamins, minerals, trace elements, carbohydrate, fat and low phenylalanine |\n| Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine |\n| Glycopyrronium |\n| Golimumab |\n| Goserelin |\n| Griseofulvin |\n| Guanfacine |\n| Guselkumab |\n| Haloperidol decanoate |\n| Heparin |\n| High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate |\n| Human Menopausal Gonadotrophin |\n| Hyaluronic acid |\n| Hydrochlorothiazide |\n| Hydroxyethyl starch 130/0.4 |\n| Ibandronic acid |\n| Ibrutinib |\n| Icosapent Ethyl |\n| Idelalisib |\n| Ifosfamide |\n| Iloprost |\n| Inclisiran |\n| IncobotulinumtoxinA |\n| Indacaterol |\n| Inotuzumab ozogamicin |\n| Insect allergen extract—honey bee venom |\n| Insect allergen extract—paper wasp venom |\n| Insect allergen extract—yellow jacket venom |\n| Insulin aspart |\n| Insulin detemir |\n| Insulin glulisine |\n| Insulin isophane |\n| Insulin lispro |\n| Insulin neutral |\n| Interferon gamma‑1b |\n| Ipilimumab |\n| Iptacopan |\n| Iron sucrose |\n| Isoleucine with carbohydrate |\n| Isoniazid |\n| Ivacaftor |\n| Ivermectin |\n| Ivosidenib |\n| Ixekizumab |\n| Ketoconazole |\n| Lanadelumab |\n| Lanthanum |\n| Lapatinib |\n| Larotrectinib |\n| Lenograstim |\n| Lenvatinib |\n| Leuprorelin |\n| Levodopa with benserazide |\n| Levonorgestrel |\n| Lidocaine |\n| Linagliptin |\n| Liothyronine |\n| Lipegfilgrastim |\n| Lisdexamfetamine |\n| Lithium |\n| Lorlatinib |\n| Lumasiran |\n| Lutropin alfa |\n| Macitentan |\n| Magnesium |\n| Mannitol |\n| Maribavir |\n| Mavacamten |\n| Mecasermin |\n| Melatonin |\n| Melphalan |\n| Mepolizumab |\n| Mesna |\n| Methoxsalen |\n| Methoxy polyethylene glycol‑epoetin beta |\n| Methoxyflurane |\n| Methylnaltrexone |\n| Miconazole |\n| Midazolam |\n| Midostaurin |\n| Mifepristone and misoprostol |\n| Migalastat |\n| Milk powder—synthetic |\n| Milk protein and fat formula with vitamins and minerals—carbohydrate free |\n| Minoxidil |\n| Molnupiravir |\n| Momelotinib |\n| Mupirocin |\n| Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish 1331 strain |\n| Mycobacterium bovis (Bacillus Calmette and Guerin), Tice strain |\n| Nafarelin |\n| Naratriptan |\n| Natalizumab |\n| Nicotine |\n| Nintedanib |\n| Nilotinib |\n| Niraparib |\n| Nivolumab |\n| Nusinersen |\n| Nystatin |\n| Obeticholic acid |\n| Obinutuzumab |\n| Ocrelizumab |\n| Odevixibat |\n| Ofatumumab |\n| Ofloxacin |\n| Olaparib |\n| Olsalazine |\n| Onasemnogene abeparvovec |\n| Opicapone |\n| Osilodrostat |\n| Osimertinib |\n| Oxcarbazepine |\n| Ozanimod |\n| Palbociclib |\n| Paliperidone |\n| Palovarotene |\n| Pancreatic extract |\n| Panitumumab |\n| Pasireotide |\n| Patiromer |\n| Patisiran |\n| Pegcetacoplan |\n| Peginterferon alfa‑2a |\n| Peginterferon Beta‑1a |\n| Pegvisomant |\n| Pembrolizumab |\n| Penicillamine |\n| Perampanel |\n| Perfluorohexyloctane |\n| Perhexiline |\n| Periciazine |\n| Permethrin |\n| Pertuzumab |\n| Phenelzine |\n| Phenobarbital |\n| Phenoxybenzamine |\n| Phenylalanine with carbohydrate |\n| Phenytoin |\n| Phytomenadione |\n| Pimecrolimus |\n| Pizotifen |\n| Poly‑l‑lactic acid |\n| Ponatinib |\n| Pralatrexate |\n| Prasugrel |\n| Primidone |\n| Probenecid |\n| Progesterone |\n| Propantheline |\n| Propylene glycol |\n| Propylthiouracil |\n| Protein formula with amino acids, carbohydrates, vitamins and minerals without phenylalanine, and supplemented with docosahexaenoic acid |\n| Protein formula with carbohydrate, fat, vitamins and minerals |\n| Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A |\n| Protein hydrolysate formula with medium chain triglycerides |\n| Pyrantel |\n| Pyridostigmine |\n| Quinagolide |\n| Raltegravir |\n| Raltitrexed |\n| Ranibizumab |\n| Ravulizumab |\n| Reboxetine |\n| Ribociclib |\n| Rifabutin |\n| Rifampicin |\n| Rifaximin |\n| Rilpivirine |\n| Riociguat |\n| Ripretinib |\n| Risankizumab |\n| Risdiplam |\n| Ritonavir |\n| Romiplostim |\n| Romosozumab |\n| Rotigotine |\n| Ruxolitinib |\n| Sacituzumab govitecan |\n| Safinamide |\n| Salmeterol |\n| Sapropterin |\n| Saxagliptin |\n| Secukinumab |\n| Selexipag |\n| Selinexor |\n| Selpercatinib |\n| Selumetinib |\n| Semaglutide |\n| Siltuximab |\n| Siponimod |\n| Sirolimus |\n| Sodium acid phosphate |\n| Sodium bicarbonate |\n| Sodium phenylbutyrate |\n| Sofosbuvir with velpatasvir |\n| Somatrogon |\n| Sonidegib |\n| Sorafenib |\n| Soy Lecithin |\n| Soy protein and fat formula with vitamins and minerals—carbohydrate free |\n| Stiripentol |\n| Sucroferric oxyhydroxide |\n| Sulthiame |\n| Tafamidis |\n| Talazoparib |\n| Tapentadol |\n| Tebentafusp |\n| Teduglutide |\n| Tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat |\n| Tepotinib |\n| Terbutaline |\n| Tetracosactide |\n| Thalidomide |\n| Theophylline |\n| Thiamine |\n| Thyrotropin alfa |\n| Tiagabine |\n| Tildrakizumab |\n| Tioguanine |\n| Tislelizumab |\n| Tofacitinib |\n| Toremifene |\n| Toripalimab |\n| Trabectedin |\n| Trametinib |\n| Trastuzumab deruxtecan |\n| Trastuzumab emtansine |\n| Travoprost |\n| Tremelimumab |\n| Trientine |\n| Trifluridine with tipiracil |\n| Triglycerides, long chain with glucose polymer |\n| Triglycerides, medium chain |\n| Triglycerides, medium chain and long chain with glucose polymer |\n| Triglycerides—medium chain, formula |\n| Trihexyphenidyl |\n| Triptorelin |\n| Tyrosine with carbohydrate |\n| Ublituximab |\n| Umeclidinium |\n| Upadacitinib |\n| Valine with carbohydrate |\n| Vanzacaftor with tezacaftor and with deutivacaftor |\n| Vedolizumab |\n| Vemurafenib |\n| Venetoclax |\n| Vericiguat |\n| Vigabatrin |\n| Vildagliptin |\n| Vinblastine |\n| Vismodegib |\n| Vitamins, minerals and trace elements formula |\n| Vitamins, minerals and trace elements with carbohydrate |\n| Vorinostat |\n| Vosoritide |\n| Vutrisiran |\n| Warfarin |\n| Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose |\n| Whey protein formula supplemented with amino acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose |\n| Zanubrutinib |\n| Zidovudine |\n| Zuclopenthixol Decanoate |\n\nSchedule 2—Drugs on F2\n\nNote: See section 7.\n\n \n\n \n\n| Abacavir with Lamivudine |\n| --- |\n| Abatacept |\n| Abiraterone |\n| Acamprosate |\n| Acarbose |\n| Aciclovir |\n| Acitretin |\n| Adalimumab |\n| Adrenaline (epinephrine) |\n| Aflibercept |\n| Alendronic acid |\n| Alendronic acid with colecalciferol |\n| Allopurinol |\n| Alprazolam |\n| Amantadine |\n| Ambrisentan |\n| Amiodarone |\n| Amisulpride |\n| Amitriptyline |\n| Amlodipine |\n| Amlodipine with Atorvastatin |\n| Amlodipine with valsartan |\n| Amlodipine with valsartan and hydrochlorothiazide |\n| Amoxicillin |\n| Amoxicillin with clavulanic acid |\n| Anastrozole |\n| Apomorphine |\n| Aprepitant |\n| Aripiprazole |\n| Arsenic |\n| Aspirin |\n| Atazanavir |\n| Atenolol |\n| Atomoxetine |\n| Atovaquone |\n| Atovaquone with proguanil |\n| Atorvastatin |\n| Azacitidine |\n| Azathioprine |\n| Azithromycin |\n| Baclofen |\n| Bendamustine |\n| Betamethasone |\n| Bevacizumab |\n| Bicalutamide |\n| Bimatoprost |\n| Bisacodyl |\n| Bisoprolol |\n| Bivalirudin |\n| Bleomycin |\n| Bortezomib |\n| Bosentan |\n| Brimonidine |\n| Brinzolamide |\n| Bromocriptine |\n| Budesonide with formoterol |\n| Buprenorphine |\n| Bupropion |\n| Cabazitaxel |\n| Cabergoline |\n| Calcipotriol with betamethasone |\n| Calcitriol |\n| Candesartan |\n| Candesartan with Hydrochlorothiazide |\n| Capecitabine |\n| Captopril |\n| Carbamazepine |\n| Carbimazole |\n| Carbomer |\n| Carboplatin |\n| Carvedilol |\n| Cefaclor |\n| Cefalexin |\n| Cefazolin |\n| Ceftriaxone |\n| Cefuroxime |\n| Celecoxib |\n| Certolizumab pegol |\n| Chorionic gonadotrophin |\n| Ciclosporin |\n| Cinacalcet |\n| Ciprofloxacin |\n| Cisplatin |\n| Citalopram |\n| Cladribine |\n| Clarithromycin |\n| Clindamycin |\n| Clomifene |\n| Clomipramine |\n| Clonazepam |\n| Clonidine |\n| Clopidogrel |\n| Clopidogrel with aspirin |\n| Clozapine |\n| Codeine with paracetamol |\n| Colchicine |\n| Cyclophosphamide |\n| Cyproterone |\n| Dabigatran etexilate |\n| Dapsone |\n| Darunavir |\n| Dasatinib |\n| Deferasirox |\n| Denosumab |\n| Desferrioxamine |\n| Desvenlafaxine |\n| Dexamethasone |\n| Dexamethasone with framycetin and gramicidin |\n| Diazepam |\n| Diclofenac |\n| Dicloxacillin |\n| Dienogest |\n| Digoxin |\n| Diltiazem |\n| Dimethyl fumarate |\n| Diphenoxylate with atropine |\n| Dipyridamole with Aspirin |\n| Docetaxel |\n| Domperidone |\n| Donepezil |\n| Dorzolamide |\n| Dorzolamide with timolol |\n| Dosulepin |\n| Doxorubicin |\n| Doxorubicin – Pegylated Liposomal |\n| Doxycycline |\n| Drospirenone |\n| Drospirenone with ethinylestradiol |\n| Duloxetine |\n| Dutasteride |\n| Dutasteride with tamsulosin |\n| Electrolyte Replacement, Oral |\n| Enalapril |\n| Enalapril with hydrochlorothiazide |\n| Enoxaparin |\n| Entecavir |\n| Epirubicin |\n| Eplerenone |\n| Epoprostenol |\n| Eprosartan |\n| Eribulin |\n| Erlotinib |\n| Erythromycin |\n| Escitalopram |\n| Esomeprazole |\n| Esomeprazole and clarithromycin and amoxicillin |\n| Estradiol |\n| Etanercept |\n| Etoposide |\n| Everolimus |\n| Exemestane |\n| Ezetimibe |\n| Ezetimibe and rosuvastatin |\n| Ezetimibe with atorvastatin |\n| Ezetimibe with simvastatin |\n| Famciclovir |\n| Famotidine |\n| Felodipine |\n| Fenofibrate |\n| Fentanyl |\n| Filgrastim |\n| Fingolimod |\n| Flecainide |\n| Flucloxacillin |\n| Fluconazole |\n| Fludarabine |\n| Fludrocortisone |\n| Fluorouracil |\n| Fluoxetine |\n| Flutamide |\n| Fluticasone propionate |\n| Fluticasone propionate with salmeterol |\n| Fluvastatin |\n| Fluvoxamine |\n| Folinic acid |\n| Follitropin Alfa |\n| Follitropin beta |\n| Fosaprepitant |\n| Fosinopril |\n| Fulvestrant |\n| Furosemide |\n| Gabapentin |\n| Galantamine |\n| Ganciclovir |\n| Ganirelix |\n| Gefitinib |\n| Gemcitabine |\n| Gemfibrozil |\n| Glatiramer |\n| Glibenclamide |\n| Gliclazide |\n| Glimepiride |\n| Glipizide |\n| Glyceryl trinitrate |\n| Granisetron |\n| Haloperidol |\n| Hydrochlorothiazide with amiloride |\n| Hydrocortisone |\n| Hydromorphone |\n| Hydroxocobalamin |\n| Hydroxycarbamide |\n| Hydroxychloroquine |\n| Hyoscine |\n| Hypromellose |\n| Hypromellose with dextran |\n| Ibuprofen |\n| Icatibant |\n| Idarubicin |\n| Imatinib |\n| Imipramine |\n| Imiquimod |\n| Indapamide |\n| Indometacin |\n| Infliximab |\n| Insulin glargine |\n| Interferon beta‑1b |\n| Ipratropium |\n| Irbesartan |\n| Irbesartan with Hydrochlorothiazide |\n| Irinotecan |\n| Iron polymaltose complex |\n| Isosorbide dinitrate |\n| Isosorbide Mononitrate |\n| Isotretinoin |\n| Itraconazole |\n| Ivabradine |\n| Labetalol |\n| Lacosamide |\n| Lamivudine |\n| Lamivudine with Zidovudine |\n| Lamotrigine |\n| Lanreotide |\n| Lansoprazole |\n| Latanoprost |\n| Latanoprost with timolol |\n| Leflunomide |\n| Lenalidomide |\n| Lercanidipine |\n| Letrozole |\n| Levetiracetam |\n| Levodopa with carbidopa |\n| Levodopa with carbidopa and entacapone |\n| Levonorgestrel with ethinylestradiol |\n| Levothyroxine |\n| Lincomycin |\n| Lisinopril |\n| Loperamide |\n| Lurasidone |\n| Macrogol 3350 |\n| Maraviroc |\n| Medroxyprogesterone |\n| Mefenamic acid |\n| Meloxicam |\n| Memantine |\n| Mercaptopurine |\n| Mesalazine |\n| Metformin |\n| Methadone |\n| Methenamine |\n| Methotrexate |\n| Methyldopa |\n| Methylphenidate |\n| Methylprednisolone |\n| Metoclopramide |\n| Metoprolol |\n| Metoprolol succinate |\n| Metronidazole |\n| Mianserin |\n| Minocycline |\n| Mirtazapine |\n| Mitozantrone |\n| Moclobemide |\n| Modafinil |\n| Mometasone |\n| Montelukast |\n| Morphine |\n| Moxonidine |\n| Mycophenolic acid |\n| Naloxone |\n| Naltrexone |\n| Naproxen |\n| Nebivolol |\n| Nevirapine |\n| Nicorandil |\n| Nifedipine |\n| Nitrazepam |\n| Nitrofurantoin |\n| Nizatidine |\n| Norethisterone |\n| Norethisterone with ethinylestradiol |\n| Norfloxacin |\n| Nortriptyline |\n| Octreotide |\n| Olanzapine |\n| Olmesartan |\n| Olmesartan with amlodipine |\n| Olmesartan with amlodipine and hydrochlorothiazide |\n| Olmesartan with hydrochlorothiazide |\n| Omalizumab |\n| Omeprazole |\n| Ondansetron |\n| Oxaliplatin |\n| Oxazepam |\n| Oxybutynin |\n| Oxycodone |\n| Oxycodone with naloxone |\n| Paclitaxel |\n| Paclitaxel, nanoparticle albumin‑bound |\n| Palonosetron |\n| Pamidronic acid |\n| Pantoprazole |\n| Paracetamol |\n| Paraffin |\n| Paroxetine |\n| Pazopanib |\n| Pegfilgrastim |\n| Pemetrexed |\n| Perindopril |\n| Perindopril with amlodipine |\n| Perindopril with indapamide |\n| Phenoxymethylpenicillin |\n| Pilocarpine |\n| Pioglitazone |\n| Pirfenidone |\n| Piroxicam |\n| Plerixafor |\n| Polyethylene glycol 400 with propylene glycol |\n| Pomalidomide |\n| Posaconazole |\n| Potassium chloride |\n| Potassium chloride with potassium bicarbonate |\n| Pramipexole |\n| Pravastatin |\n| Prazosin |\n| Prednisolone |\n| Prednisone |\n| Pregabalin |\n| Prochlorperazine |\n| Propranolol |\n| Quetiapine |\n| Quinapril |\n| Quinine |\n| Rabeprazole |\n| Raloxifene |\n| Ramipril |\n| Ranitidine |\n| Rasagiline |\n| Riluzole |\n| Risedronic acid |\n| Risperidone |\n| Rituximab |\n| Rivaroxaban |\n| Rivastigmine |\n| Rizatriptan |\n| Rosuvastatin |\n| Roxithromycin |\n| Salbutamol |\n| Sacubitril with valsartan |\n| Selegiline |\n| Sertraline |\n| Sevelamer |\n| Sildenafil |\n| Simvastatin |\n| Sitagliptin |\n| Sitagliptin with metformin |\n| Somatropin |\n| Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate |\n| Sotalol |\n| Spironolactone |\n| Sulfasalazine |\n| Sumatriptan |\n| Sunitinib |\n| Tacrolimus |\n| Tadalafil |\n| Tamoxifen |\n| Telmisartan |\n| Telmisartan with amlodipine |\n| Telmisartan with Hydrochlorothiazide |\n| Temazepam |\n| Temozolomide |\n| Tenofovir |\n| Tenofovir with emtricitabine |\n| Tenofovir with emtricitabine and efavirenz |\n| Terbinafine |\n| Teriflunomide |\n| Teriparatide |\n| Testosterone |\n| Tetrabenazine |\n| Ticagrelor |\n| Timolol |\n| Tiotropium |\n| Tirofiban |\n| Tobramycin |\n| Tocilizumab |\n| Tolvaptan |\n| Topiramate |\n| Topotecan |\n| Tramadol |\n| Trandolapril |\n| Tranexamic acid |\n| Tranylcypromine |\n| Trastuzumab |\n| Triamcinolone |\n| Triamcinolone with neomycin, gramicidin and nystatin |\n| Trimethoprim |\n| Trimethoprim with sulfamethoxazole |\n| Ursodeoxycholic acid |\n| Ustekinumab |\n| Valaciclovir |\n| Valganciclovir |\n| Valproic acid |\n| Valsartan |\n| Valsartan with hydrochlorothiazide |\n| Vancomycin |\n| Varenicline |\n| Venlafaxine |\n| Verapamil |\n| Vildagliptin with metformin |\n| Vincristine |\n| Vinorelbine |\n| Voriconazole |\n| Ziprasidone |\n| Zoledronic acid |\n| Zolmitriptan |\n| Zonisamide |\n\nEndnotes\n\nEndnote 1—About the endnotes\n\nThe endnotes provide information about this compilation and the compiled law.\n\nThe following endnotes are included in every compilation:\n\nEndnote 1—About the endnotes\n\nEndnote 2—Abbreviation key\n\nEndnote 3—Legislation history\n\nEndnote 4—Amendment history\n\nAbbreviation key—Endnote 2\n\nThe abbreviation key sets out abbreviations that may be used in the endnotes.\n\nLegislation history and amendment history—Endnotes 3 and 4\n\nAmending laws are annotated in the legislation history and amendment history.\n\nThe legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.\n\nThe amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.\n\nEditorial changes\n\nThe Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.\n\nIf the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.\n\nMisdescribed amendments\n\nA misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.\n\nIf a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.\n\nEndnote 2—Abbreviation key\n\n \n\n| ad = added or inserted | orig = original |\n| --- | --- |\n| am = amended | p = page(s) |\n| amdt = amendment | para = paragraph(s)/subparagraph(s) |\n| C[x] = Compilation No. x | /sub‑subparagraph(s) |\n| ch = Chapter(s) | pres = present |\n| cl = clause(s) | prev = previous |\n| cont. = continued | (prev…) = previously |\n| def = definition(s) | pt = Part(s) |\n| Dict = Dictionary | r = regulation(s)/Court rule(s) |\n| disallowed = disallowed by Parliament | reloc = relocated |\n| div = Division(s) | renum = renumbered |\n| ed = editorial change | rep = repealed |\n| exp = expires/expired or ceases/ceased to have | rs = repealed and substituted |\n| effect | s = section(s)/subsection(s) |\n| gaz = gazette | /rule(s)/subrule(s)/order(s)/suborder(s) |\n| LA = Legislation Act 2003 | sch = Schedule(s) |\n| LIA = Legislative Instruments Act 2003 | SLI = Select Legislative Instrument |\n| (md) = misdescribed amendment can be given | SR = Statutory Rules |\n| effect | sub ch = Sub‑Chapter(s) |\n| (md not incorp) = misdescribed amendment | sub div = Subdivision(s) |\n| cannot be given effect | sub pt = Subpart(s) |\n| mod = modified/modification | underlining = whole or part not |\n| No. = Number(s) | commenced or to be commenced |\n| Ord = Ordinance |  |\n\n\n \n\nEndnote 3—Legislation history\n\n \n\n| Name | Registration | Commencement | Application, saving and transitional provisions |\n| --- | --- | --- | --- |\n| National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021) | 31 Mar 2021 (F2021L00390) | 1 Apr 2021 (s 2(1) item 1) |  |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 3) (PB 45 of 2021) | 30 Apr 2021 (F2021L00524) | 1 May 2021 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 4) (PB 54 of 2021) | 28 May 2021 (F2021L00657) | 1 June 2021 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 5) (PB 81 of 2021) | 31 July 2021 (F2021L01061) | 1 Aug 2021 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 6) (PB 93 of 2021) | 31 Aug 2021 (F2021L01217) | 1 Sept 2021 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 7) (PB 103 of 2021) | 30 Sept 2021 (F2021L01371) | 1 Oct 2021 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 8) (PB 115 of 2021) | 31 Oct 2021 (F2021L01491) | 1 Nov 2021 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 9) (PB 125 of 2021) | 30 Nov 2021 (F2021L01638) | 1 Dec 2021 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 1) (PB 7 of 2022) | 31 Jan 2022 (F2022L00086) | 1 Feb 2022 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 2) (PB 18 of 2022) | 28 Feb 2022 (F2022L00199) | 1 Mar 2022 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 3) (PB 29 of 2022) | 31 Mar 2022 (F2022L00458) | 1 Apr 2022 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 4) (PB 40 of 2022) | 29 Apr 2022 (F2022L00649) | 1 May 2022 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 5) (PB 64 of 2022) | 30 June 2022 (F2022L00886) | 1 July 2022 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 6) (PB 75 of 2022) | 29 July 2022 (F2022L01020) | 1 Aug 2022 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 7) (PB 83 of 2022) | 31 Aug 2022 (F2022L01143) | 1 Sept 2022 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 8) (PB 95 of 2022) | 30 Sept 2022 (F2022L01296) | 1 Oct 2022 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 9) (PB 104 of 2022) | 31 Oct 2022 (F2022L01413) | 1 Nov 2022 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 10) (PB 116 of 2022) | 30 Nov 2022 (F2022L01553) | 1 Dec 2022 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 11) (PB 125 of 2022) | 23 Dec 2022 (F2022L01761) | 1 Jan 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 1) (PB 6 of 2023) | 31 Jan 2023 (F2023L00066) | 1 Feb 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 2) (PB 27 of 2023) | 31 Mar 2023 (F2023L00393) | 1 Apr 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 3) (PB 39 of 2023) | 28 Apr 2023 (F2023L00492) | 1 May 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 4) (PB 48 of 2023) | 31 May 2023 (F2023L00658) | 1 June 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 5) (PB 62 of 2023) | 30 June 2023 (F2023L00930) | 1 July 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 6) (PB 74 of 2023) | 31 July 2023 (F2023L01048) | 1 Aug 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 7) (PB 87 of 2023) | 31 Aug 2023 (F2023L01149) | 1 Sept 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 8) (PB 97 of 2023) | 29 Sept 2023 (F2023L01345) | 1 Oct 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 9) (PB 109 of 2023) | 31 Oct 2023 (F2023L01450) | 1 Nov 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 10) (PB 119 of 2023) | 30 Nov 2023 (F2023L01577) | 1 Dec 2023 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 1) (PB 7 of 2024) | 31 Jan 2024 (F2024L00127) | 1 Feb 2024 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 2) (PB 34 of 2024) | 28 Mar 2024 (F2024L00419) | 1 Apr 2024 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 3) (PB 45 of 2024) | 30 Apr 2024 (F2024L00495) | 1 May 2024 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 4) (PB 58 of 2024) | 31 May 2024 (F2024L00609) | 1 June 2024 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 5) (PB 74 of 2024) | 28 June 2024 (F2024L00827) | 1 July 2024 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 6) (PB 81 of 2024) | 31 July 2024 (F2024L00952) | 1 Aug 2024 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 7) (PB 92 of 2024) | 30 Aug 2024 (F2024L01101) | 1 Sept 2024 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 8) (PB 103 of 2024) | 30 Sept 2024 (F2024L01247) | 1 Oct 2024 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 9) (PB 119 of 2024) | 31 Oct 2024 (F2024L01392) | 1 Nov 2024 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 10) (PB 129 of 2024) | 29 Nov 2024 (F2024L01530) | 1 Dec 2024 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination 2024 (No. 11) (PB 143 of 2024) | 24 Dec 2024 (F2024L01738) | 1 Jan 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 1) 2025 (PB 8 of 2025) | 31 Jan 2025 (F2025L00069) | 1 Feb 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 2) 2025 (PB 19 of 2025) | 28 Feb 2025 (F2025L00223) | 1 Mar 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 3) 2025 (PB 32 of 2025) | 31 Mar 2025 (F2025L00464) | 1 Apr 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 4) 2025 (PB 50 of 2025) | 30 Apr 2025 (F2025L00541) | 1 May 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 5) 2025 (PB 61 of 2025) | 30 May 2025 (F2025L00633) | 1 June 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 6) 2025 (PB 79 of 2025) | 27 June 2025 (F2025L00779) | 1 July 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 7) 2025 (PB 90 of 2025) | 31 July 2025 (F2025L00876) | 1 Aug 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 8) 2025 (PB 99 of 2025) | 29 Aug 2025 (F2025L01018) | 1 Sept 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 9) 2025 (PB 115 of 2025) | 30 Sept 2025 (F2025L01217) | 1 Oct 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 10) 2025 (PB 128 of 2025) | 31 Oct 2025 (F2025L01313) | 1 Nov 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 11) 2025 (PB 141 of 2025) | 28 Nov 2025 (F2025L01461) | 1 Dec 2025 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 12) 2025 (PB 160 of 2025) | 24 Dec 2025 (F2025L01662) | 1 Jan 2026 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 1) 2026 (PB 11 of 2026) | 30 Jan 2026 (F2026L00058) | 1 Feb 2026 (s 2(1) item 1) | — |\n| National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 2) 2026 (PB 23 of 2026) | 27 Feb 2026 (F2026L00179) | 1 Mar 2026 (s 2(1) item 1) | — |\n\n\n \n\nEndnote 4—Amendment history\n\n \n\n| Provision affected | How affected |\n| --- | --- |\n| s 2..................... | rep LA s 48D |\n| s 4..................... | rep LA s 48C |\n| Schedule 1 |  |\n| Schedule 1................ | am F2021L00524; F2021L00657; F2021L01061; F2021L01217 |\n|  | ed C4 |\n|  | am F2021L01371; F2021L01491; F2021L01638; F2022L00086; F2022L00199; F2022L00458; F2022L00649; F2022L00886; F2022L01020; F2022L01143; F2022L01296; F2022L01413; F2022L01553; F2022L01761; F2023L00066; F2023L00393; F2023L00492; F2023L00658; F2023L00930; F2023L01048; F2023L01149; F2023L01345; F2023L01450; F2023L01577; F2024L00127; F2024L00419; F2024L00495; F2024L00609; F2024L00827; F2024L00952; F2024L01101; F2024L01247; F2024L01392; F2024L01530; F2024L01738; F2025L00069; F2025L00223; F2025L00464; F2025L00541; F2025L00633; F2025L00779; F2025L00876; F2025L01018; F2025L01217; F2025L01313; F2025L01461; F2025L01662; F2026L00058; F2026L00179 |\n| Schedule 2 |  |\n| Schedule 2................ | am F2021L00657; F2021L01061; F2021L01217; F2021L01371; F2021L01491; F2021L01638; F2022L00086; F2022L00458; F2022L01020; F2022L01296; F2022L01553; F2023L00066; F2023L00393; F2023L00658; F2023L01048; F2023L01149; F2023L01345; F2023L01577; F2024L00127; F2024L00419; F2024L00609; F2024L01101; F2024L01247; F2024L01530; F2025L00069; F2025L00464; F2025L00541; F2025L00633; F2025L00779; F2025L00876; F2025L01217; F2025L01313; F2025L01461; F2026L00058 |\n| Schedule 3................ | rep LA s 48C |\n\n \n","sortOrder":0}],"analysis":{"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"},"kimi_summary":{"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"The legislation remains a straightforward listing instrument. Despite 53 amendments since 2021, it has not expanded beyond its original purpose of categorising PBS-listed drugs into F1 and F2. The schedules have grown longer (more drugs added) but the legal mechanism and scope remain identical to the original 2021 determination."},"complexity_factors":["Extremely short operative provisions—only 7 sections, with sections 2 and 4 repealed and section 5 containing a single definition","No conditional logic, exceptions, or cross-references within the substantive provisions (sections 6 and 7 are one-line directives)","Complexity is entirely contained in the two schedules (F1 and F2), which are simple alphabetical lists of drug names without regulatory text","No nested definitions, no application provisions, no transitional arrangements in the body of the instrument","Amendment history shows 53 separate amending instruments, but these merely add/remove items from the schedules rather than complicating the structure"],"plain_english_summary":"This instrument is the government’s master list of medicines subsidised under the PBS, split into F1 (mostly newer, high‑cost or specialised drugs with tighter prescribing controls) and F2 (common, established medicines with simpler access). It matters to patients, prescribers, pharmacists and drug companies because it determines subsidy eligibility, patient co‑payments, prescribing rules and access restrictions. This version incorporates updates through March 2026, including new cancer and rare‑disease therapies."},"flash_summary":{"complexity_score":4,"scope_assessment":{"changed":false,"description":"The instrument’s legal function — to declare listed drugs as on F1 or F2 for subsection 85AB(1) — has not changed. What has changed is the content of the lists: Schedule 1 and Schedule 2 have been repeatedly amended to add, remove or modify entries (see Endnotes 3 and 4), but the determination’s scope and purpose remain the same."},"complexity_factors":["Large, detailed enumerations: Schedule 1 and Schedule 2 together list hundreds of drugs and specific formulations (Schedules 1–2).","Frequent amendment history: multiple monthly/annual amendments are recorded in Endnote 3 and Endnote 4, increasing maintenance and tracking burden.","Statutory cross‑reference: the determination operates only for the purposes of subsection 85AB(1) of the National Health Act 1953, requiring coordination with the Act (ss 3, 6–7).","Interpretive specificity: many entries name formulations and combinations (e.g. amino‑acid formulas, fixed combinations), which can create line‑drawing questions for practitioners and suppliers (Schedules 1–2).","Reliance on compilation and endnotes: users must consult endnotes for amendment, commencement and editorial changes, adding administrative complexity (About this compilation; Endnotes 1–4).","Presentational/editorial modifications authorised under the Legislation Act 2003, so the published compilation may differ in form from original instruments (Compilation notes)."],"plain_english_summary":"This instrument lists specific medicines and formulations and formally declares them to be “on F1” or “on F2” for the purposes of subsection 85AB(1) of the National Health Act 1953 (ss 6–7). It changes which named drugs fall into each category by placing them in Schedule 1 or Schedule 2. The determination affects persons and agencies governed by subsection 85AB(1) because those classifications carry legal effect under the Act; the schedules are updated frequently (see endnotes)."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-listed-drugs-on-f1-or-f2-determination-2021","history":"/api/acts/national-health-listed-drugs-on-f1-or-f2-determination-2021/history","analysis":"/api/acts/national-health-listed-drugs-on-f1-or-f2-determination-2021/analysis","conflicts":"/api/acts/national-health-listed-drugs-on-f1-or-f2-determination-2021/conflicts","importantCases":"/api/acts/national-health-listed-drugs-on-f1-or-f2-determination-2021/important-cases","documents":"/api/acts/national-health-listed-drugs-on-f1-or-f2-determination-2021/documents"}}